mejiaoneto

6 ms·

1.
Shasqi (YC W15) Hiring Directors of Translational Sciences, Medicinal Chemistry
1 points by mejiaoneto 6y ago
2.
Shasqi (YC W15) Is Hiring 2 (USA-Remote) Executive Assistants(linkedin.com)
1 points by mejiaoneto 6y ago
3.
by mejiaoneto 6y ago
Thank you for your comment. We have an investigational product, which means it can only be used in the context of a clinical trial. All products that eventually reach the clinic have to go through this step and rigorous testing before being
4.
by mejiaoneto 6y ago
That is correct. It is a retro diels alder reaction. Here is a link to an earlier report from us, that has the chemical structures: https://pubs.acs.org/doi/full/10.1021/acscentsci.6b00150
5.
by mejiaoneto 6y ago
Thank you. We are very proud of what the team has accomplished and optimistic based on what the CAPAC platform has shown in preclinical studies. The unique aspect of this is that it is based on chemistry not biology so it seems that the rep
6.
by mejiaoneto 6y ago
Thank you for your wishes. Nothing special about doxorubicin. This is a broad technology that can be applied to many cancer therapies, including radionuclides as you as asked. I agree with your comments on using a known agent.
7.
by mejiaoneto 6y ago
Yes. Any solid tumor that is accesible for an injection and we have reason to suspect it would be sensitive to doxorubicin, would fit the criteria of this phase 1 study. For more info on the clinical trial please visit: https://c
8.
by mejiaoneto 6y ago
Thank you for your comment. Our approach increases the extracellular concentration of Dox and then it does the same job that it usually does.
9.
by mejiaoneto 6y ago
I am sorry to hear that. With regards to your point about liquid biopsies. To have a minimally invasive sensitive and specific test would be a great addition to the toolbox against cancer. However, if it comes back positive, then what comes
10.
by mejiaoneto 6y ago
Because this cannot be achieved with one dose. Also think about diffusion in tissue of small molecules. Essentially within an hour or two, anything that you injected in the tumor is gone. So now you are asking about killing everything with
11.
by mejiaoneto 6y ago
Exactly. For us at Shasqi, it was about combining the spatial control of surgery with the temporal control (flexibility of dosing) of oral or intravenous drugs.
12.
by mejiaoneto 6y ago
Thank you for your comments. With regards to your questions. On chemo leading to cytotoxic vs immune killing I am not sure that we have reached the point of a consensus on this. I would say that there is more and more evidence of the involv
13.
by mejiaoneto 6y ago
I am not sure that there is any one path or unique suggestion. But my general advice was to stay curious, learn as much as possible and keep an eye for what could be, rather than just accepting things as they are. Also I strongly believe in
14.
by mejiaoneto 6y ago
Thank you for sharing. The book looks interesting, but I have not read it yet, so I cannot comment.
15.
by mejiaoneto 6y ago
That is absolutely right. By honing the drug to the tumor, and minimizing the effects on the rest of the body, you are essentially able to unlock power on the tumor that would have put the patient's life at risk before. Taken it even
16.
by mejiaoneto 6y ago
The CAPAC technology allows you to give multiple daily doses of the therapy for 5 consecutive days after injecting the tumor with the biopolymer once. This is a significant advantage to needing to inject the tumor daily.
17.
by mejiaoneto 6y ago
Thank you for your comment. Congratulations on your positive response and recovery. Our goal is to enable the same response in others who may experience side effects and may have to forgo treatment because of it. Doxorubicin, also nicknamed
18.
by mejiaoneto 6y ago
In addition, for those who are interested in learning more, here are two pre-print manuscripts that we submitted this week. This one talks about the effect of our therapy on local and distant tumors: https://www.biorxiv.org/
19.
by mejiaoneto 6y ago
1. Cancer is characterized as local tumor, locoregional or distant (metastasis). 2. Our approach can certainly help patients with local or locoregional disease. 3. As we have presented in multiple cancer conferences, our approach seems to
20.
by mejiaoneto 6y ago
Thank you for your thoughts and question. There has been a recent wave of intratumoral approaches particularly for immunooncology (e.g. TLR, Sting, oncolytic viruses) and there are manuscripts in the scientific literature about the technica
21.
by mejiaoneto 6y ago
Sorry to hear about your girlfriend. I have heard those feelings as well. They are not uncommon. The probability of success changes as you move further in the development. Below there is a link for a booklet that talks about the general pha
22.
by mejiaoneto 6y ago
Historically, and probably the mainstream hypothesis, is that you need chemo to be systemic in order to take care of micrometastatic disease (tumors that you cannot see). However, with the advent of immunooncology (IO) therapies (drugs that
23.
by mejiaoneto 6y ago
That is an interesting question. Thank you for sharing. Indeed, I was a chemistry PhD before going to medical school. Unfortunately, there are no easy shortcuts that I know of. Interestingly it is a bit unpredictable if somebody will pract
24.
by mejiaoneto 6y ago
This is Jose, CEO of Shasqi. There are three firsts that Shasqi announced this morning: 1. First time click chemistry is used in humans. 2. First YC company to reach first-in-human clinical trials 3. First two patients dosed for SQ3370 in
25.
Shasqi (YC W15) aims to make chemotherapy more powerful and less toxic(forbes.com)
138 points by mejiaoneto 6y ago|56 comments
26.
Shasqi (YC W15) unveils a new way to deliver drugs in the body(pubs.acs.org)
12 points by mejiaoneto 10y ago|0 comments